Prion diseases are fatal neurodegenerative disorders characterized by accumulation of 24 PrP Sc , vacuolation of neurons and neuropil, astrocytosis, and microglial activation. 25 Up-regulation of gene expressions of innate immunity-related factors including complement 26 factors and CD14 is observed in the brains of mice infected with prions even in the early stage 27 of infections. When CD14 knockout (CD14 -/-) mice were infected intracerebrally with the 28 Chandler and Obihiro prion strains, the mice survived longer than wild-type (WT) mice, 29 suggesting that CD14 influences the progression of the prion disease. Immunofluorescence 30 staining that can distinguish normal prion protein from the disease-specific form of prion 31 protein (PrP Sc ) revealed that deposition of PrP Sc was delayed in CD14 -/mice when compared 32 with WT mice by the middle stage of the infection. Immunohistochemical staining with Iba1, 33 a marker for activated microglia, showed an increased microglial activation in prion-infected 34 CD14 -/mice than in WT mice. Interestingly, accompanied by the increased microglial 35 activation, anti-inflammatory cytokines IL-10 and TGF-β, appeared to be expressed earlier in 36 prion-infected CD14 -/mice. In contract, IL-1β expression appeared to be reduced in the 37 CD14 -/mice in the early stage of infection. Double immunofluorescence staining 38 demonstrated that CD11b-and Iba1-positive microglia mainly produced the 39 anti-inflammatory cytokines, suggesting anti-inflammatory status of microglia in the CD14 -/-40 mice in the early stage of infection. These results imply that CD14 plays a role in the disease 41 progression by suppressing anti-inflammatory responses in the brain in the early stage of 42 infection.
Immunohistochemistry. For the antigen retrieval of Iba1 detection in paraffin embedded 177 tissue, the slides were treated with microwaves at 600W for 10 min in 0.01M Citrate buffer 178 solution pH6.0. After washing with PBS, the slides were blocked with normal goat serum 179 (Nichirei) and incubated overnight with primary antibody diluted at 1:1000 in normal goat 180 serum at 4˚C. The slides were treated with 0.3% hydrogen peroxide in methanol to block 181 endogenous peroxidase activity at rt for 10 min. Biotin-labeled anti-rabbit IgG goat 182 9 polyclonal antibodies (Nichirei) were incubated for 10 min at rt. Peroxidase-labeled 183 streptoavidin (Nichirei) was reacted for 5 min at rt. The immunoreactivity was visualized with 184 Impact DAB (Vector). For the quantitative analysis of the number of Iba1-positive microglia, 185 cells with more than 10 μm 2 of Iba1 immunoreactivity was counted by Image J (Rasband, W. , 1997-2009) . 188 For the immunohistochemistry of the microglial markers and cytokines in frozen tissue, 189 brains were embedded in the OCT compound (Sakura Finetek Japan) and were cut at a 190 thickness of 10 μm. Sections were fixed with 4% PFA for 10 min at rt. For the antigen 191 retrieval, samples were treated with 0.1% Tween20 in PBS for 15 min at rt. The slides were 192 blocked with 2% bovine serum albumin for 15 min at rt, incubated overnight with primary 193 antibody at 4˚C. Then, slides were incubated with secondary antibodies and DAPI for 1h at rt. 194 Finally slides were mounted with ProLong Gold Anti-fade Reagent (Invitrogen) and observed 195 with LSM700 (Zeiss) or (Nikon) . For the detection of CD14, CD45, and CD68, the antibodies 196 were diluted at 1:800. For CD11b, TGF-β, and IL-1β, the antibodies were diluted at 1: 200. 197 For IL-10, the antibody was diluted at 1:100. For GFAP and F4/80, the antibodies were 198 diluted at 1:1000. For secondary antibodies, all Alexa Fluor-labeled antibodies were diluted at 199 1:1000. (Fig. 1A) . The CD14 gene expression in the thalamus of the 208 Chandler-infected mice was 2.5 ± 0.8, 3.6 ± 0.8, and 3.6 ± 0.6 higher than that in the thalamus 209 of mock-infected mice, at 75, 90, and 120 dpi, respectively, confirming the up-regulation of 210 CD14 expression. We also performed immunofluorescence staining of frozen sections of the 211 Chandler-and Obihiro-infected mice brains to confirm the protein expression of CD14 (Fig. 212 1B), and CD14-positive cells were most frequently detected in the cerebral peduncle at the 213 observed time points (Fig. 1B) . The CD14-positive cells were scattered in corpus callosum, 214 internal capsules, and cerebral peduncles at 60 dpi, spreading more widely in the cerebral 215 peduncles and periventricle areas at 90 dpi, and the spreading had expanded to the thalamus at 216 120 dpi ( Fig. 1B & C) . A few CD14-positive cells were also detected in the internal capsules 217 and cerebral peduncles of mock-infected mouse brains suggesting that these cells may be 218 residents in these areas (Fig. 1C ). To confirm the CD14 expression in the microglia, double 219 staining of the CD14 with CD11b for microglia and of the GFAP for astrocytes were 220 performed ( Fig. 1D ). Most of the CD14 immunoreactivity was detected in the CD11b-positive 221 microglia, but it was not detected in the GFAP-positive astrocytes. 
CD14 influences the progression of prion diseases.
To examine the effect of the lack of 224 CD14 on the neuropathogenesis of prion diseases, we inoculated brain homogenates of the 225 Chandler or Obihiro strain-infected mice into CD14 -/mice (Fig. 2) . The CD14 -/mice 226 infected either with the Chandler or Obihiro strains survived longer than the WT mice. The 227 mean survival time of the Chandler strain-infected CD14 -/mice (161.7 ± 3.7 days, n = 11) 228 11 was significantly longer than that of the WT mice (153.8 ± 3.7 days, n = 12, p<0.01, Student's 229 t-test, Figs. 2A) . The mean survival time of the Obihiro strain-infected CD14 -/mice (172.3 ± 230 4.8 days, n = 10) was also significantly longer than that of WT mice (157.9 ± 7.8 days, n = 11, 231 p<0.01, Student's t-test, Fig. 2B ). These results suggest that the lack of CD14 decelerates the 232 progression of the disease.
233
To determine if knockout of CD14 influences the accumulation of PrP Sc , we analyzed the 234 PrP-res accumulation in the brains by immunoblotting (Figs. 3A & B) . The intensity of the 235 PrP Sc signals in the brains of CD14 -/mice infected with either the Chandler or the Obihiro 236 strains was slightly reduced at 90 and 120 dpi, and became comparable to those of the WT 237 mice at the terminal stage. 238 We have reported that mAb132 recognizing amino acid 119-127 of mouse PrP, in 239 combination with pre-treatment of cells with 5M guanidine thiocyanate, is useful for the 240 PrP Sc -specific immunofluorescence staining of prion-infected cell cultures (21). It is well 241 established that PrP Sc includes protease-sensitive and protease-resistant PrP Sc (23, 24) . The 242 protease-sensitive PrP Sc that cannot be detected by immunoblotting using proteinase K-treated 243 samples could be detected by this PrP Sc -specific immunofluorescence staining because of the 244 omission of protease treatment process. In the present study we applied this method to brain 245 frozen sections for the detection of PrP Sc (Figs. 3C & D) . Signals of PrP could be detected 246 from the brains of prion-infected mice but signals from the brains of uninfected mice 247 remained at background levels under the same condition (data not shown), demonstrating that 248 this method can be applied to detect PrP Sc from brain frozen sections. At 60 dpi, bright 249 punctuate staining of PrP Sc was detected frequently in the thalamus and occasionally detected 250 in the cerebral cortex of the WT mice infected with the Chandler strain. The PrP Sc was also 251 WT and CD14 -/mice infected with the Chandler strain ( Fig. 3D ). However, the PrP Sc staining 255 in some brain areas of CD14 -/mice seemed to be still weaker than in the WT mice (Figs. 3C 256 & D). There were no marked differences in the PrP Sc distribution between the WT and CD14 -/-257 mice at 120 dpi. Delay of the PrP Sc accumulation was also observed in the brains of the 258 Obihiro-infected CD14 -/mice. At 60 dpi, PrP Sc was detected in the hippocampus and 259 thalamus of WT mice, but not in these areas of the CD14 -/mice. At 90 dpi, PrP Sc was spread 260 into the hypothalamus and amygdala of WT mice, but the presence of PrP Sc in the CD14 -/-261 mice was restricted to the hippocampus and thalamus. 262 We also analyzed the prion infectivity in the brains of WT and CD14 -/mice using Tga20 263 mice that overexpress mouse PrP and thus are highly susceptible to mouse-adapted prions 264 (25). Prion infectivity in the brains of both of 2 Chandler-infected CD14 -/mice at 60 dpi were 265 significantly lower than those from both of 2 WT mice ( Fig. 4 ). Prion infectivity in the brains 266 of the Obihiro-infected mice also appeared to be lower than those from WT mice; the 267 infectivity in the brain of one CD14 -/mouse (No.2) was significantly lower than those of one 268 WT mouse (No.1). However, in the later stages, there were no significant differences in the 269 prion infectivity of WT and CD14 -/mice in the Chandler-or Obihiro-infection ( Fig. 4 ) 270 We also performed a histopathological analysis of the brains of WT and CD14 -/mice 271 infected with the Chandler strain ( Fig. 5 ). At 90 dpi, slight vacuolar degeneration of neuropil 272 and neurons was only occasionally observed in in the thalamus of Chandler-infected WT and 273 CD14 -/mice. Vacuolar degeneration was widely observed throughout the brains after 120 dpi; 274 13 however, there was no apparent difference in the severity and distribution of vacuolar 275 degeneration of the WT and CD14 -/mice infected with the Chandler strain. CD14 altered microglial activation in prion diseases, we analyzed the expression of an 280 activated microglial marker Iba1 by immunohistochemistry ( Fig. 6 ). At 60 dpi, some 281 microglia of CD14 -/mice had more protrusions than those of WT mice. Morphological 282 differences in Iba1-positive microglia became more prominent at 90 dpi; microglia in CD14 -/-283 mice had a larger cytoplasm and more branched protrusions than those of WT mice. At 120 284 dpi, Iba1-positive microglia in WT mice had a smaller cytoplasm and fewer protrusions; 285 however, microglia in CD14 -/mice still had relatively larger cytoplasm with many 286 protrusions. In the terminal stage, there were no obvious differences in the morphology of 287 microglia between WT and CD14 -/mice.
288
The quantitative analysis of Iba1 positive microglia showed that in the hippocampus and 289 thalamus of the Chandler-infected WT and CD14 -/mice the numbers of microglia increased 290 from 60 to 120 dpi, then showed no further change or slightly decreased ( Fig. 6B ). Similar 291 changes were observed in the Obihiro-infected WT and CD14 -/mice. In the 292 Chandler-infected mice, there was little difference in the numbers of Iba1-positive microglia 293 between the WT and CD14 -/mice by 90 dpi. At 120 dpi, Iba1-positive microglia increased 294 more in the thalamus of CD14 -/mice than in WT mice. In the terminal stage, numbers of the 295 Iba1-positive microglia decreased both in WT and CD14 -/mice, although those in the 296 thalamus of CD14 -/mice were still slightly larger than those of WT mice. In the 297 mice. In the terminal stage, there were no marked differences in the numbers of Iba1-positive 301 microglia between WT and CD14 -/mice.
302
To further characterize the differences in microglial activation of prion-infected WT and 303 CD14 -/mice, we performed immunofluorescence staining for other microglial markers ( Fig.   304 7). Expression of CD11b, a commonly used microglial marker, was elevated in the brains of 305 WT and CD14 -/mice from 90 to 120 dpi, and the expression of CD11b in CD14 -/mice was 306 more intense than that in WT mice at each time point. A marker for macrophages and 307 monocytes, F4/80, is also frequently used as a microglial marker. Similar to CD11b, F4/80 308 immunoreactivity was detected more in CD14 -/mice than in WT mice at 90 and 120 dpi.
309
Similar changes were also observed in the immunofluorescence staining for CD68, a 310 phagocytic marker of macrophages and microglia: CD68-positive cells increased 311 time-dependently both in WT and CD14 -/mice, and CD68 immunoreactivity was more observations (data not shown). (17), 373 suggesting that CD14 could also play a role in other neurodegenerative disorders. However, 374 microglial activation is different in prion-infected and AD model mice lacking CD14; 375 microglia in CD14 -/mice infected with prions were more strongly activated than in WT mice 376 particularly in the early stage of the disease, whereas there is reduced microglial activation in 377 AD model mice lacking CD14 (17).
378
There is a line of evidence that microglial activation causes detrimental effects in prion 379 diseases. For instance, there is a report that a blockade of the colony stimulating factor 1 380 receptor (CSF1R) signaling pathway reduced microglial proliferation in the brains of 381 prion-infected mice and slowed the disease progression (31). Prion-infected mice deficient for 382 CD40 ligand showed shortened incubation periods with increased microglial activation (32).
383
Furthermore, prion-infected CXCR3 deficient mice survived longer than WT mice with 384 reduced microglial activation, although prion propagation and PrP Sc accumulation were 385 accelerated (33). On the contrary, here we showed that microglia were more activated in 386 prion-infected CD14 -/mice than in WT mice, but that prion-infected CD14 -/mice survived 
401
Although an accelerating role of CD14 in the progression of prion diseases is suggested 402 by the current study, the mechanism for how the CD14 works in the process of the disease 403 needs to be further elucidated. One possible involvement of CD14 indicated by the results of 404 the immunofluorescence staining for anti-inflammatory cytokines is that it down-regulates 405 alternative activation of microglia directly or indirectly. Induction of a pro-inflammatory 406 response is another possible function of CD14 in prion diseases. The CD14 is a 407 GPI-anchoring protein and thus lacks an intracellular domain, but it works together with the 408 TLR4 homodimer to induce cellular signaling involved in pro-inflammatory responses (12).
409
Therefore, a lack of CD14 affects the signaling through the CD14/TLR4 complex which 410 could be a cause of the longer survival of prion-infected CD14 -/mice. However, a previous 411 study showed that TLR4-signaling mutant mice, C3H/HeJ (Tlr4 Lps-d ) mice, possessing a single 412 suggesting that TLR4 signaling can interfere with the disease progression (35). This is 414 seemingly paradoxical to the results of our study here. However, TLR4 is not the only 415 counterpart of CD14: CD14 is reported to form clusters with a TLR2-TLR6 heterodimer (36). activity facilitated cerebral inflammation and acute neuronal death in ME7-infected mice (9).
436
IL-10 has been reported to have a neuroprotective role by blocking caspase-3-like activity 437 (41). and TGF-β also promotes neuronal survival by up-regulating anti-apoptotic Bcl-2 family 438 proteins (42). Therefore, an earlier expression of these anti-inflammatory cytokines may 439 partially contribute to the prolonged survival of CD14 -/mice. Furthermore, both IL-10 and 440 TGF-β provide anti-inflammatory effects by down-regulating pro-inflammatory mediators 441 such as IL-1β, [43] [44] [45] . Indeed, expression of IL-1β in some brain 442 regions of CD14 -/mice appeared to be lower than in WT mice (Fig. 10 ). However, it is also 443 possible that the lower expression of IL-1β here resulted from a lack of TLR-CD14 signaling accumulation (1, 56) . Thus, the delayed PrP Sc 456 accumulation in the early stage of the disease in CD14 -/mice may imply the existence of a 457 brain niche with accelerated microglial activation that may provide anti-prion propagation 458 21 conditions particularly at the early stage of the disease.
459
In this study, we showed that the increased activation of microglia accompanied by the Chandler-infected mice. The areas positive for IL-10 (µm 2 /0.1 mm 2 ) were quantified using 728 Imaris ver 7.6.1 (Bitplane). The numbers of mice used for the analysis were 3 both of WT and 729 30 CD14 -/mice at 60 dpi, 2 both of WT and CD 14 -/mice at 90 dpi and 2 of WT mice at 120 dpi, The areas positive for IL-10 (µm 2 /0.1mm 2 ) were quantified using Imaris ver 7.6.1 (Bitplane). The numbers of mice used for the analysis were 3 both of WT and CD14 -/mice at 60 dpi, 2 both of WT and CD 14 -/mice at 90 dpi and 2 of WT mice at 120 dpi, and 1 of CD14 -/mouse at 120 dpi. ＊p<0.01, Student's t-test. 
